Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Texas: - UT Southwestern Medical Center — Dallas, Texas
- Local Institution - 2127 — Houston, Texas
- MD Anderson Cancer Center — Houston, Texas
- Local Institution - 2146 — Kingwood, Texas
Phase 1, Phase 2 Recruiting Industry
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific KRAS mutation. This is an open-label study which means that participants a…
Sponsor: Arvinas Inc.
NCT ID: NCT07023731
Sites in Texas: - Clinical Trial Site — Houston, Texas
- Clinical Trial Site — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Sponsor: ModeX Therapeutics, An OPKO Health Company
NCT ID: NCT06239194
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
- NEXT Oncology — San Antonio, Texas
Phase 2 Recruiting Academic/Other
This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research s…
Sponsor: Massachusetts General Hospital
NCT ID: NCT05668962
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Academic/Other
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less …
Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT05783323
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Academic/Other
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less …
Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT06458036
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Academic/Other
To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT06959511
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 1 Recruiting Industry
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two par…
Sponsor: Pfizer
NCT ID: NCT05538130
Sites in Texas: - University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 1 Recruiting Industry
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is …
Sponsor: Pfizer
NCT ID: NCT05355701
Sites in Texas: - START San Antonio — San Antonio, Texas
Phase 1 Recruiting Industry
This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.
Sponsor: Solve Therapeutics
NCT ID: NCT06771219
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
- Oncology Consultants — Houston, Texas
- Mays Cancer Center; University of Texas Health San Antonio — San Antonio, Texas
Phase 1 Recruiting Academic/Other
This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cel…
Sponsor: City of Hope Medical Center
NCT ID: NCT03975231
Sites in Texas: - Univ of Texas-M.D. Anderson Cancer Center — Houston, Texas
Phase 1 Recruiting Academic/Other
This trial investigates whether hyperpolarized magnetic resonance imaging (hpMRI) can predict treatment response in patients with thyroid cancer and other malignancies of the head and neck undergoing radiation therapy and/or receiving syst…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04589624
Sites in Texas: - M D Anderson Cancer Center — Houston, Texas
Phase 1 Recruiting Academic/Other
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest tolerable dose of gemcitabine that can be given by inhalation (breath…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT03093909
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Texas: - The Don and Sybil Harrington Cancer Center — Amarillo, Texas
- Saint Joseph Regional Cancer Center — Bryan, Texas
- M D Anderson Cancer Center — Houston, Texas
- Doctor's Hospital of Laredo — Laredo, Texas
- Audie L Murphy VA Hospital — San Antonio, Texas
NA Recruiting Network
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in Texas: - Saint Joseph Regional Cancer Center — Bryan, Texas
- University of Texas Health Science Center at San Antonio — San Antonio, Texas
Recruiting Industry
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …
Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in Texas: - Elligo Health Research, Inc. — Austin, Texas
Recruiting Industry
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…
Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Texas: - Research Site — Dallas, Texas
Recruiting Academic/Other
Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC ha…
Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT05024929
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
- Texas Children's Hospital — Houston, Texas
Recruiting Academic/Other
This study utilizes a multi-institutional registry to describe the natural history of medullary thyroid cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) in understand…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04216732
Sites in Texas: - M D Anderson Cancer Center — Houston, Texas
NA Recruiting Academic/Other
This study is to evaluate the effectiveness of nsPFA in treating papillary thyroid microcarcinoma. T
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT07218315
Sites in Texas: - The University of Texas M. D. Anderson Cancer Center — Houston, Texas
Recruiting Academic/Other
To find good information about medullary thyroid cancer that is easy to understand and reliable, so researchers aim to design some new educational materials to help.
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT07142005
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
NA Recruiting Academic/Other
This trial compares cryoablation combined with stereotactic body radiation therapy to stereotactic body radiation therapy alone to see how well they work in treating patients with pain from cancer that has spread to the bones (bone metasta…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04693377
Sites in Texas: - M D Anderson Cancer Center — Houston, Texas
Recruiting Academic/Other
To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in this study.
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT07140757
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Recruiting Academic/Other
Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical de…
Sponsor: The University of Texas Health Science Center at San Antonio
NCT ID: NCT03160274
Sites in Texas: - University of Texas Health Science Center — San Antonio, Texas
Recruiting Academic/Other
The goal of this clinical research study is to learn about the barriers in the real world to accessing treatments for ATC. And to learn about how patients with ATC tolerate and respond to the commercially available medications for treatmen…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT06507878
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas